Augustine Lawlor - 28 Mar 2025 Form 4 Insider Report for LEAP THERAPEUTICS, INC. (LPTX)

Footnote F1

22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 14,703 of such shares and the Company withheld on such settlement date the remaining 7,797 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 7,797 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.

Footnote F2

The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023.

Footnote F3

Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock.

Footnote F4

Includes (i) 2,136 shares of Common Stock held by Nine Capital Partners, (ii) 414,480 shares of Common Stock held by HealthCare Ventures IX, L.P. ("HCV IX"), and (iii) 261,840 shares of Common Stock held by the HCV VIII Trust ("HCV Trust"). The reporting person is a managing member of Nine Capital Partners and may be deemed to have beneficial ownership of the 2,136 shares of Common Stock held by Nine Capital Partners.

Footnote F5

The reporting person is a Managing Director of HCPIX LLC, which is the General Partner of HealthCare Partners IX, which is the General Partner of HCV IX, and the reporting person may be deemed to have beneficial ownership of the 414,480 shares of Common Stock held by HCV IX. The reporting person is a beneficiary of the HCV Trust and may be deemed to have beneficial ownership of the 261,840 shares of Common Stock held by the HCV Trust. The reporting person disclaims beneficial ownership of such shares of Common Stock held by each of Nine Capital Partners, HCV IX, and the HCV Trust, except to the extent of the reporting person's proportionate pecuniary interest in such shares of Common Stock.

Footnote F6

The January 2022 RSUs became fully vested on January 31, 2025 but settlement thereof was deferred by the Compensation Committee of the Board of Directors of the Company until March 28, 2025 pursuant to, and in accordance with, the terms of the January 2022 RSUs, which terms provide that the Compensation Committee would have the authority to defer the settlement of the January 2022 RSUs to a date later than the vesting date of the January 2022 RSUs in the event that on such vesting date the reporting person were to be subject to, among other things, any limitation or restriction under the Company's insider trading policy that would not permit the reporting person to sell on such vesting date all of the shares of the Company's Common Stock underlying the January 2022 RSUs if the January 2022 RSUs were to be settled on such vesting date.

Footnote F7

The Compensation Committee of the Board of Directors took action to defer settlement of the January 2022 RSUs so that such settlement would not occur on January 31, 2025, the vesting date thereof. The January 2022 RSUs were settled on March 28, 2025 on a net issue basis as further described on note (2) above.

Footnote F8

The terms of the January 2022 RSUs provide that the January 2022 RSUs would automatically terminate and be forfeited upon termination of the reporting person's employment or other service relationship with the Company if such termination of employment or service relationship were to occur at any time prior to January 31, 2022, the vesting date of the January 2022 RSUs.